A5008116540- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nanowire Synthesis and Applications
- Cell Adhesion Molecules Research
- Neuroinflammation and Neurodegeneration Mechanisms
- T-cell and B-cell Immunology
- Advancements in Semiconductor Devices and Circuit Design
- Immune cells in cancer
- Glioma Diagnosis and Treatment
- Cellular Mechanics and Interactions
- Angiogenesis and VEGF in Cancer
University of California, Los Angeles
2017-2024
Abstract Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to escape and tumor relapse exists. Here we report the rational design optimization of bispecific CAR-T cells with robust activity heterogeneous multiple myeloma (MM) that is resistant conventional targeting maturation (BCMA). We demonstrate BCMA/CS1 exhibit superior CAR expression function compared T co-express individual BCMA CS1 CARs....
Cytokine release syndrome (CRS) is a frequently observed side effect of chimeric antigen receptor (CAR)-T cell therapy. Here, we report self-regulating T cells that reduce CRS severity by secreting inhibitors cytokines associated with CRS. With humanized NSG-SGM3 mouse model, show reduced CRS-related toxicity in mice treated CAR-T tocilizumab-derived single-chain variable fragment (Toci), yielding safety profile superior to single-dose systemic tocilizumab administration. Unexpectedly,...
Abstract Background Glioblastoma, while considered rare, is characterized by poor survival and few treatment advances for over 20 years. New options brain cancers are, therefore, desperately needed. Active research that being conducted in immunotherapy glioblastoma other primary may be hampered the lack of detailed studies characterize different immune compartments orthotopic murine tumor models. Methods We used glioma neural stem cell lines derived from patients to produce intracranial...
ABSTRACT Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies but also demonstrated marked vulnerability to escape and tumor relapse. Here, we report the rational design systematic optimization of bispecific CAR-T cells with robust activity multiple myeloma (MM), including heterogeneous MM that is resistant conventional targeting maturation (BCMA). We demonstrate BCMA/CS1 exhibit significantly higher CAR expression levels greater...